Free Trial

PTC Therapeutics (PTCT) Competitors

PTC Therapeutics logo
$47.63 -0.90 (-1.85%)
Closing price 04:00 PM Eastern
Extended Trading
$47.62 -0.01 (-0.02%)
As of 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PTCT vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, ASND, QGEN, BPMC, and BBIO

Should you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.

PTC Therapeutics vs. Its Competitors

PTC Therapeutics (NASDAQ:PTCT) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

PTC Therapeutics has a net margin of 33.56% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat PTC Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PTC Therapeutics33.56% -78.56% 32.11%
Intra-Cellular Therapies -14.07%-9.93%-8.38%

Intra-Cellular Therapies has lower revenue, but higher earnings than PTC Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PTC Therapeutics$806.78M4.68-$363.30M$6.517.32
Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64

PTC Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.

PTC Therapeutics currently has a consensus price target of $65.00, indicating a potential upside of 36.47%. Intra-Cellular Therapies has a consensus price target of $109.70, indicating a potential downside of 16.81%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe PTC Therapeutics is more favorable than Intra-Cellular Therapies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PTC Therapeutics
1 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.67
Intra-Cellular Therapies
0 Sell rating(s)
10 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

In the previous week, PTC Therapeutics had 11 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 12 mentions for PTC Therapeutics and 1 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 0.29 beat PTC Therapeutics' score of 0.09 indicating that Intra-Cellular Therapies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PTC Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Intra-Cellular Therapies
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

92.3% of Intra-Cellular Therapies shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

PTC Therapeutics beats Intra-Cellular Therapies on 11 of the 17 factors compared between the two stocks.

Get PTC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTCT vs. The Competition

MetricPTC TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.85B$2.91B$5.52B$9.41B
Dividend YieldN/A2.45%3.80%4.04%
P/E Ratio7.3219.8828.0419.84
Price / Sales4.68305.11429.5399.59
Price / CashN/A43.1635.8457.94
Price / Book-3.347.678.125.65
Net Income-$363.30M-$55.28M$3.25B$258.00M
7 Day Performance-1.89%2.50%0.97%2.09%
1 Month Performance-5.55%11.70%7.36%11.13%
1 Year Performance45.17%4.89%31.31%18.40%

PTC Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTCT
PTC Therapeutics
4.4456 of 5 stars
$47.63
-1.9%
$65.00
+36.5%
+41.9%$3.85B$806.78M7.321,410News Coverage
Insider Trade
Analyst Revision
ITCI
Intra-Cellular Therapies
0.9187 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.9168 of 5 stars
$20.52
+1.1%
$37.60
+83.2%
-18.0%$13.16B$3.12B11.662,682Analyst Revision
RDY
Dr. Reddy's Laboratories
2.7536 of 5 stars
$15.08
flat
$16.95
+12.4%
-6.6%$12.59B$3.81B22.8527,811News Coverage
Upcoming Earnings
MRNA
Moderna
4.2835 of 5 stars
$29.90
-1.9%
$46.61
+55.9%
-74.0%$11.56B$3.24B-3.425,800Trending News
Options Volume
Analyst Revision
RGC
Regencell Bioscience
0.2214 of 5 stars
$18.43
-19.8%
N/AN/A$11.37BN/A0.0010Gap Up
VTRS
Viatris
3.2683 of 5 stars
$9.20
-1.3%
$10.40
+13.0%
-21.7%$10.80B$14.74B-2.9032,000Trending News
ASND
Ascendis Pharma A/S
3.6333 of 5 stars
$175.98
+1.0%
$220.67
+25.4%
+27.9%$10.76B$393.54M-28.021,017Positive News
QGEN
QIAGEN
3.7474 of 5 stars
$47.49
-1.8%
$49.40
+4.0%
+16.9%$10.56B$1.98B119.075,765Positive News
BPMC
Blueprint Medicines
1.0832 of 5 stars
$128.40
+0.0%
$128.06
-0.3%
+13.2%$8.29B$508.82M-51.98640News Coverage
Positive News
BBIO
BridgeBio Pharma
4.6238 of 5 stars
$43.50
-1.1%
$58.85
+35.3%
+67.0%$8.26B$221.90M-12.32400Analyst Revision

Related Companies and Tools


This page (NASDAQ:PTCT) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners